Vivos Therapeutics Gains AMA Approval for New Medical Codes, Expanding Access to Sleep Apnea Treatment
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics has received approval from the American Medical Association for new CPT medical codes for its Vivos CARE oral devices, effective January 1, 2025. This approval is expected to enhance insurance coverage and accessibility for their sleep apnea treatments, potentially driving revenue growth.
October 08, 2024 | 11:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Vivos Therapeutics has secured AMA approval for new CPT codes for its sleep apnea treatment devices, effective January 2025. This is expected to improve insurance coverage and accessibility, potentially boosting revenue.
The AMA's approval of new CPT codes for Vivos' devices will facilitate insurance coverage, making their treatments more accessible. This regulatory milestone is likely to increase demand and drive revenue growth, positively impacting VVOS stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100